CRUK Convergence Science Centre

What CRUK Convergence Science Centre does

The CRUK Convergence Science Centre is a non-profit research partnership between Imperial College London and The Institute of Cancer Research, funded primarily through Cancer Research UK as a designated Major Centre. Operating from London across Imperial's South Kensington and White City campuses and ICR's Chelsea location, the Centre applies a convergence science approach that integrates engineering, physical sciences, life sciences, and medicine to address intractable challenges in cancer research. Its core infrastructure includes a Human Organoid Facility and biobank for patient-derived cancer models, a Microfabrication and Prototyping Facility with 2-micron resolution SU8 clean-room capabilities for microfluidic devices and organs-on-chip, and a Cancer Technology Catalyst team providing implementation science, health economics, and biostatistics expertise.

The Centre runs a portfolio of training and funding programmes: a four-year Non-clinical PhD programme with tracks including Black Leaders In Cancer, Chemical Biology, Statistics and Machine Learning, and CRUK Convergence Science; an Intercalated PhD pathway for medical undergraduates (4 studentships per cohort, 3-year duration); and Clinical Research Training Fellowships (up to 4 per year, up to £287,288 over 3 years). It also provides seed funding through a Development Fund offering up to £80,000 per 12-month project. The Centre's revenue model is grant-based rather than commercial, distributing funds to researchers at Imperial and ICR whose work aligns with its four research themes: Convergence Discovery Research, Interventional Science, Clinical Drug Development, and Data Science and Digital Pathology. Emerging AI/ML capabilities include foundation models for immunotherapy prediction, transformer-based DeepMorph for blood morphology, and multi-omics integration for biomarker discovery.

The Centre serves an exclusively academic and clinical end-user base: researchers, PhD students, and clinical fellows at Imperial and ICR, with clinical translational access through partner NHS trusts (Royal Marsden and Imperial College Healthcare). Its go-to-market is community-led, engaging researchers through seminars, workshops, an annual symposium, and direct institutional channels. Notable strategic milestones include its 2016 founding, 2018 CRUK Major Centre designation, 2020 appointment of Professor Axel Behrens as Scientific Director, and 2022 merger of three predecessor CRUK centres into its current unified form.

Name

CRUK Convergence Science Centre

Legal name

Cancer Research UK Convergence Science Centre

Website

https://convergencesciencecentre.ac.uk

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

The CRUK Convergence Science Centre is a non-profit research partnership between Imperial College London and The Institute of Cancer Research, funded by Cancer Research UK. It integrates engineering, physical sciences, and medicine to advance cancer research through specialized infrastructure, PhD training programmes, and seed funding for interdisciplinary researchers at its two partner institutions.

Ownership category

akta.pro rank

Product category

Cancer Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Clinical Research & Trial Central Laboratories (HLAFAMAL), Research & Science Grantmaking Foundations (BPAGAKAI)

Keywords

• Cancer research center
• Convergence science training
• Translational research infrastructure
• Clinical research fellowships
• Interdisciplinary biomedical research

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Grant Funding: The Centre is funded primarily through Cancer Research UK Major Centre grant. It provides seed funding (Development Fund up to £80,000), PhD studentships, and clinical research fellowships to researchers at Imperial and ICR.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

The CRUK Convergence Science Centre is a non-profit research partnership between Imperial College London and The Institute of Cancer Research that delivers convergence science cancer research by providing shared research infrastructure (organoid biobank, microfabrication and prototyping facilities, Cancer Technology Catalyst), training programmes (Non-Clinical PhD, Intercalated PhD, Clinical Research Training Fellowships), and seed funding (Development Fund) to affiliated researchers and clinicians.

Product overview

The CRUK Convergence Science Centre is a partnership between Imperial College London and The Institute of Cancer Research, focused on convergence science that integrates engineering, physical sciences, life sciences and medicine to address challenges in cancer research. The Centre offers a portfolio of research infrastructure including the Human Organoid Facility, Microfabrication and Prototyping Facility, and Cancer Technology Catalyst, alongside clinical trial infrastructure through The Oak Foundation Drug Development Unit and Imperial Clinical Trial Unit. Training offerings include Non-Clinical PhD programmes (Black Leaders In Cancer, Chemical Biology, Statistics and Machine Learning, CRUK Convergence Science), Intercalated PhD for medical students, and Clinical Research Training Fellowships. The Centre also provides seed funding through its Development Fund (up to £80,000 for 12-month projects). Research activities span convergence discovery research, interventional science, clinical drug development, and data science with digital pathology, with emerging AI capabilities including foundation models for immunotherapy prediction, deep learning for pathology and radiology, and multi-omics integration for biomarker discovery.

Differentiator

Problem solved

Functional benefit

Products and services

• Human Organoid Facility A cutting-edge organoid culture facility and biobank enabling researchers to create and cultivate patient-derived cancer organoids and other three-dimensional cancer models for translational cancer research.
• Microfabrication and Prototyping Facility A facility at Imperial College South Kensington and White City campuses for rapid prototyping of microfluidic devices, organs-on-chip, biosensors, electrochemical sensors, and microneedles for pre-clinical and in vitro cancer diagnostics, with clean room, 3D printing, laser cutting, electronics, and SU8 mask-free PDMS multilayer device production at 2-micron resolution.
• Cancer Technology Catalyst A dedicated team of specialists in implementation science, health economics, clinical positioning, biostatistics and epidemiology who use a Team Science approach to gather evidence and accelerate the translation of cancer innovations into clinical practice.
• Development Fund (Seed Funding) A seed funding initiative providing up to £80,000 for 12-month projects to foster new collaborations and generate disruptive ideas at the interfaces of life, clinical, engineering, and physical sciences for cancer research.
• Convergence Science Non-Clinical PhD Programme Four-year fully-funded PhD programmes including Black Leaders In Cancer, Chemical Biology (with ICB), Statistics and Machine Learning (StatML with EPSRC), and CRUK Convergence Science tracks, training researchers in integrating biology, engineering and physical sciences for cancer research.
• Intercalated PhD (iPhD) Programme A pathway for medical undergraduates enrolled in the MBBS/BSc degree to pursue an intercalated PhD in convergence science cancer research, equipping clinical academics with expertise integrating cancer research with engineering and physical sciences, offering 4 studentships per cohort (2027 intake) with a tax-free fixed stipend of £24,219 per year plus fees.
• Clinical Research Training Fellowship Up to 4 highly competitive clinical PhD fellowships for early-career clinicians providing world-class training in cancer research and convergence science, typically three years in duration with funding up to £287,288 covering clinical salary, PhD registration fees at UK rate, and research running costs.

Quantifiable outcome

• Brings together researchers from different disciplines to develop innovative ways to address challenges in cancer research and improve patient outcomes
• +1 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Imperial College LondoncoreStrategic or Co-development Partner · 1 January 2016Primary institutional partner. The Centre is a partnership between ICR and Imperial College London. Imperial provides research expertise across engineering, physical sciences, and life sciences. The Centre is recognised as a Centre of Excellence within Imperial.
• The Institute of Cancer Research (ICR)coreStrategic or Co-development Partner · 1 January 2016Primary institutional partner. The Centre is a partnership between ICR and Imperial College London. ICR is one of the world's most influential cancer research organisations. The Centre is recognised as a research division within the ICR.
• Royal Marsden NHS Foundation TrustcoreStrategic or Co-development PartnerPartner NHS trust for clinical collaboration. The Royal Marsden opened in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education. Joint NIHR Biomedical Research Centre for Cancer with ICR. Home to The Oak Foundation Drug Development Unit.
• Imperial College Healthcare NHS TrustcoreStrategic or Co-development PartnerPartner NHS trust providing acute and specialist healthcare in north west London for around a million people every year. Formed in 2007. Supports clinical collaboration and translational research.
• NIHR Biomedical Research CentresminorStrategic or Co-development PartnerCollaborates with local NIHR Biomedical Research Centres, centres and networks of excellence across partner institutions and clinical units for translational research support.
• NIHR Experimental Cancer Medicine CentresminorStrategic or Co-development PartnerCollaborates with Experimental Cancer Medicine Centres across partner institutions for clinical research support.

Scale indicators4 records

Recent moves10 records

Expansion highlights5 records

Broad incumbents

• European Molecular Biology Laboratory (EMBL): Intergovernmental research organisation in molecular life sciences with multi-site infrastructure, training, and technology development mandates. Comparable as a multi-site European research organisation with infrastructure and training programmes, though broader and intergovernmental in nature.
• Wellcome Sanger Institute: UK genomics and biomedical research institute with large-scale research infrastructure and training programmes. Comparable in scale of infrastructure and training pipeline, though focused primarily on genomics rather than broader convergence science.
• National Cancer Institute (NCI): US federal agency funding cancer research, training, and infrastructure across US institutions. Comparable in mission scope (cancer research funding, training, infrastructure), though operating at national scale rather than as a single centre.
• Memorial Sloan Kettering Cancer Center: Major US cancer research and treatment centre integrating laboratory science, clinical research, and training. Comparable in combining cancer research, clinical translation, and training, though operating at much larger scale with hospital ownership.
• MRC Laboratory of Molecular Biology (LMB): UK Medical Research Council-funded biomedical research institute with strong training programmes and technology development. Comparable as a UK research institute combining basic research, infrastructure access, and training, though narrower in disciplinary scope than a convergence centre.

Direct peers

• Broad Institute of MIT and Harvard: US institute explicitly built on a convergence model integrating biology, chemistry, mathematics, computation, and engineering to drive disease research. Highly comparable to the CRUK Centre's stated convergence science remit and cross-institutional structure.
• Francis Crick Institute: UK biomedical research institute with explicit interdisciplinary science across physical and life sciences, funded primarily by CRUK along with Wellcome and other partners. Closely comparable as a CRUK-supported interdisciplinary biomedical research organisation in London.
• CRUK Manchester Institute: CRUK Major Centre embedded within the University of Manchester conducting basic and translational cancer research. Comparable as another CRUK Major Centre with research, training, and infrastructure programmes serving a major UK research university.
• CRUK Cambridge Centre: Another CRUK Major Centre bringing together University of Cambridge cancer researchers across disciplines. Directly comparable as a CRUK-funded multi-institutional cancer research centre with funding, training, and infrastructure mandates.

Others

• Karolinska Institutet Comprehensive Cancer Centre: Swedish academic cancer research centre integrating research, training, and clinical translation. Comparable as an academic cancer research centre with multidisciplinary programmes; Scientific Advisory Board chair Prof Sir David Lane previously led Karolinska research, suggesting active scientific community overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cruk-convergence-science-centre

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CRUK Convergence Science Centre